TRCT
INTS icon

Tower Research Capital (TRC)’s Intensity Therapeutics INTS Stock Holding History

Tower Research Capital (TRC)’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.13K Buy
1,984
+1,917
+2,861% +$9.01K ﹤0.01% 4095
2026
Q1 		$394 Sell
67
-794
-92% -$6.48K ﹤0.01% 4886
2025
Q4 		$8.83K Buy
861
+194
+29% +$1.97K ﹤0.01% 3932
2025
Q3 		$4.05K Buy
667
+127
+24% +$908 ﹤0.01% 4410
2025
Q2 		$4.14K Buy
540
+445
+468% +$9.14K ﹤0.01% 4373
2025
Q1 		$4.68K Sell
95
-11
-10% -$612 ﹤0.01% 4217
2024
Q4 		$4.66K Buy
106
+59
+126% +$4.28K ﹤0.01% 4423
2024
Q3 		$4.43K Sell
47
-47
-50% -$5.22K ﹤0.01% 4546
2024
Q2 		$11.6K Sell
94
-187
-67% -$21.2K ﹤0.01% 4073
2024
Q1 		$37.5K Buy
+281
New +$33.7K ﹤0.01% 2472
2023
Q4 		– Sell
-41
Closed -$4.29K – 6046
2023
Q3 		$4.29K Buy
+41
New +$5.66K ﹤0.01% 4890

Other funds holding INTS

KWM
KMT Wealth Management El Segundo, California $118M AUM 26.19% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.25B AUM 22.33% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80B AUM 26.12% 1-Year Est. Return

Tower Research Capital (TRC)'s INTS Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Intensity Therapeutics (INTS) stake by 2,861% in Q2 2026, buying an estimated $9.01K and bringing the position to 1,984 shares worth $8.13K. The position accounts for ﹤0.01% of the portfolio, ranked #4095.

Tower Research Capital (TRC) first reported a position in INTS in Q3 2023 and has held it in 11 quarters since. The position peaked at $37.5K in Q1 2024. 14 funds tracked by Wall St. Rank hold INTS as of Q2 2026.

  • Tower Research Capital (TRC) held 1,984 shares of Intensity Therapeutics worth $8.13K as of Q2 2026.
  • Tower Research Capital (TRC) bought 1,917 Intensity Therapeutics shares in Q2 2026, an estimated $9.01K.
  • Intensity Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4095 holding.
  • Tower Research Capital (TRC) first reported a position in Intensity Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • Tower Research Capital (TRC)'s Intensity Therapeutics position peaked at $37.5K in Q1 2024.
  • 14 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.